His primary areas of study are Internal medicine, Immunology, Immunotherapy, Colorectal cancer and Oncology. His Internal medicine study combines topics in areas such as Gastroenterology and Surgery. He has researched Immunotherapy in several fields, including Cytotoxic T cell and Dendritic cell, Antigen.
His study on Oxaliplatin is often connected to In patient as part of broader study in Colorectal cancer. His Oncology research is multidisciplinary, incorporating elements of Cohort and Adenocarcinoma. While the research belongs to areas of Immune system, Michael A. Morse spends his time largely on the problem of In vivo, intersecting his research to questions surrounding Cellular immunity.
Internal medicine, Oncology, Immunology, Immune system and Immunotherapy are his primary areas of study. The Internal medicine study combines topics in areas such as Gastroenterology and Surgery. His work on Renal cell carcinoma as part of general Oncology study is frequently linked to In patient, therefore connecting diverse disciplines of science.
In his study, Clinical trial and Antibody is strongly linked to Cancer, which falls under the umbrella field of Immunology. Michael A. Morse works mostly in the field of Immune system, limiting it down to concerns involving Cancer research and, occasionally, Breast cancer. The various areas that he examines in his Immunotherapy study include Carcinoembryonic antigen and Melanoma.
Michael A. Morse mainly focuses on Internal medicine, Oncology, Cancer research, Cancer and Immunotherapy. In the field of Internal medicine, his study on Colorectal cancer, Adverse effect and Chemotherapy overlaps with subjects such as In patient. His work carried out in the field of Oncology brings together such families of science as Tolerability, Irinotecan, Oxaliplatin, Clinical endpoint and Nivolumab.
His Cancer research research incorporates elements of Immune checkpoint, T cell, Metastasis, Breast cancer and Antitumor activity. His Cancer study integrates concerns from other disciplines, such as Melanoma and Immune system. His Immunotherapy study is concerned with the larger field of Immunology.
Michael A. Morse mainly investigates Internal medicine, Oncology, Nivolumab, Immunotherapy and Colorectal cancer. Michael A. Morse regularly ties together related areas like Gastroenterology in his Internal medicine studies. His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Tyrosine-kinase inhibitor, Concomitant, Surgery and Prior Therapy.
His research in Nivolumab intersects with topics in Ipilimumab and Carcinoma. His study with Immunotherapy involves better knowledge in Immunology. His work on DNA mismatch repair, Irinotecan and Oxaliplatin as part of general Colorectal cancer research is frequently linked to Microsatellite instability, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Steven J. Cohen;Cornelis J.A. Punt;Nicholas Iannotti;Bruce H. Saidman.
Journal of Clinical Oncology (2008)
The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells
Cole Trapnell;Davide Cacchiarelli;Davide Cacchiarelli;Jonna Grimsby;Prapti Pokharel.
Nature Biotechnology (2014)
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Christine H. Chung;Beloo Mirakhur;Emily Chan;Quynh Thu Le.
The New England Journal of Medicine (2008)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman;Ray McDermott;Joseph L. Leach;Sara Lonardi.
Lancet Oncology (2017)
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay.
Journal of The National Comprehensive Cancer Network (2007)
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Matthew T. Roe;Paul W. Armstrong;Keith A.A. Fox;Harvey D. White.
The New England Journal of Medicine (2012)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott.
Lancet Oncology (2016)
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
Michael A Morse;Jennifer Garst;Takuya Osada;Shubi Khan.
Journal of Translational Medicine (2005)
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz.
Journal of Clinical Oncology (2018)
Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.
S K Nair;D Boczkowski;M Morse;R I Cumming.
Nature Biotechnology (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: